MTSL Issue 998
MTSL Issue 998 (dated 3/30/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #CLDX #celldex #INCY #incyte #IONS #ionis #MYOV #myovant #SGMO #sangamo #VKTX #viking #ZYNE #zynerba
Sorting Through The Rubble
BIOINVEST SPECIAL UPDATE – Biotechs were under pressure this week as the sudden failure of SVB and drug pricing concerns delivered a double whammy in a continued rising rate environment. In our view, while all biotech stocks are being sold indiscriminately, we believe (…more)
Myovant (MYOV) — Myovant Accepts $27 From Sumitovant – Downgrade To Hold
BIOINVEST BREAKING NEWS – Last night, MTSL Recommendation MYOV announced that its board has accepted a $2.9 billion (fully-diluted) takeover offer from Sumitovant Biopharma for $27 per share. While we believed that the original $22.50 offer was way too low, the final price does represent (…more)
MoneyShow’s Accredited Investors Virtual Expo (October 12, 2022)
Please join BioInvest FREE at The MoneyShow live streaming event on October 12 where John McCamant will be presenting along with dozens of the most respected economists, money managers, and professional traders in the country. #MYOV #MDGL #PGEN #TCRT
MTSL Issue 986
MTSL Issue 986 (dated 10/06/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #ionis #MDGL #madrigal #MYOV #myovant
Myovant (MYOV) — In Our View, Majority-Owner Sumitovant Biopharma Proposed $22.75 Takeover Is Way Too Low – BUY
BIOINVEST BREAKING NEWS – Last night, MTSL Recommendation MYOV announced that its board gracefully declined a $2.4 billion takeover offer from Sumitovant Biopharma, a unit of Japan-based Sumitomo Pharma. Sumitovant owns 52% of MYOV shares and offered $22.75, a price that we find to be way too low. (…more)
MTSL Issue 982
MTSL Issue 982 (dated 08/11/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #BMRN #biomarin #BCYC #bicycle #CLDX #celldex #ESPR #esperion #IONS #ionis #INCY #incyte #MDGL #madrigal #MYOV #myovant #PGEN #precigen #SGMO #sangamo #VXRT #vaxart #ZYNE #zynerba
Good Medicine for Biotechs
BIOINVEST SPECIAL UPDATE – Good Medicine for Biotechs: Great Data, Awesome Sales, Monster Deals Yesterday; 100+% Premium Acquisition Today. (…more)
MTSL Issue 981
MTSL Issue 981 (dated 07/28/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #IONS #ionis #INCY #incyte #MYOV #myovant #VXRT #vaxart
MTSL Issue 976
MTSL Issue 976 (dated 05/19/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #TCRT #alaunos #CLDX #celldex #INCY #incyte #MDGL #madrigal #MYOV #myovant #PCRX #pacira #VXRT #vaxart
MTSL Issue 974
MTSL Issue 974 (dated 04/13/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #CLDX #celldex #ESPR #esperion #IONS #ionis #MYOV #myovant
Myovant (MYOV) — FDA Delays MYOV/Pfizer Approval for Endometriosis on Labeling/Post-marketing Requirements
BIOINVEST BREAKING NEWS – FDA Delays MYOV/Pfizer Approval for Endometriosis on Labeling. MYOV and their partner Pfizer announced today a delay on the Supplemental New Drug Application (sNDA) for MYFEMBREE for the management of moderate to severe pain associated with endometriosis. In our view, this is clearly a delay and not a rejection. (…more)
MTSL Issue 971
MTSL Issue 971 (dated 03/03/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #CLDX #celldex #IONS #ionis #MDGL #madrigal #NKTR #nektar #PCRX #pacira #SGMO #sangamo #VXRT #vaxart #ZYNE #zynerba
MTSL Issue 968
MTSL Issue 968 (dated 01/20/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #INCY #incyte #IONS #ionis #MDGL #madrigal #MYOV #myovant #NKTR #nektar #PGEN #precigen
MTSL Issue 967
MTSL Issue 967 (dated 01/06/22) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #MDGL #madrigal #MYOV #myovant #PCRX #pacira #PLXP #plxpharma #SGMO #sangamo
MTSL Issue 963
MTSL Issue 963 (dated 10/28/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #IONS #ionis #MYOV #myovant #PGEN #precigen #VXRT #vaxart
MTSL Issue 962
MTSL Issue 962 (dated 10/14/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #MYOV #myovant $PCRX #pacira #PLXP #plxpharma #PGEN #precigen #VXRT #vaxart
MTSL Issue 953
MTSL Issue 953 (dated 5/27/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #MYOV #myovant #NKTR #nektar #PCRX #pacira
MTSL Issue 952
MTSL Issue 952 (dated 5/13/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #CLDX #celldex #ESPR #esperion #MYOV #myovant #NKTR #nektar #PGEN #precigen #VXRT #vaxart #ZIOP #ziopharm #ZYNE #zynerba
MTSL Issue 950
MTSL Issue 950 (dated 4/15/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #CLDX #celldex #INCY #incyte #IONS #ionis #MYOV #myovant #PCRX #pacira #ZIOP #ziopharm
MTSL Issue 946
MTSL Issue 946 (dated 2/18/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #INCY #incyte #MYOV #myovant #NKTR #nektar
MTSL Issue 944
MTSL Issue 944 (dated 1/21/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #FPRX #fiveprime #MYOV #myovant #NKTR #nektar #PGEN #precigen#ZIOP #ziopharm
MTSL Issue 943
MTSL Issue 943 (dated 1/07/21) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #ESPR #esperion #MYOV #myovant #NKTR #nektar #PCRX #pacira #PGEN #precigen
MTSL Issue 940
MTSL Issue 940 (dated 11/19/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #ESPR #esperion #MDGL #madrigal #MYOV #myovant #PCRX #pacira #PGEN #precigen #VXRT #vaxart #ZIOP #ziopharm
MTSL Issue 937
MTSL Issue 937 (dated 10/08/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #ESPR #esperion #INCY #incyte #MDGL #madrigal #MYOV #myovant #PCRX #pacira #SGMO #sangamo #VXRT #vaxart
Myovant (MYOV) — Regugolix HERO Data Equivalent But Not Superior to Leuprolide in Castration Resistance-Free Survival, Remains on Track For Approval With Dec. 20 PDUFA
BIOINVEST BREAKING NEWS – MYOV announced results of an additional secondary endpoint from the Phase III HERO study evaluating relugolix in men with advanced prostate cancer. Relugolix did not achieve statistical superiority for castration resistance-free survival compared to leuprolide acetate in men with metastatic disease through 48 weeks. (…more)
MTSL Issue 934
MTSL Issue 934 (dated 08/27/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ALKS #alkermes #CLDX #celldex #MYOV #myovant #PGEN #precigen
MTSL Issue 933
MTSL Issue 933 (dated 08/13/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #BMRN #biomarin #CLDX #celldex #ESPR #esperion #IONS #ionis #INCY #incyte #IONS #ionis #MDGL #madrigal #MYOV #myovant #NKTR #nektar #PCRX #pacira #PGEN #precigen #SGMO #sangamo #VXRT #vaxart #ZIOP #ziopharm #ZYNE #zynerba
MTSL Issue 931
MTSL Issue 931 (dated 07/16/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #ionis #MYOV #myovant #PCRX #pacira #VXRT #vaxart #ZIOP #ziopharm
MTSL Issue 930
MTSL Issue 930 (dated 07/02/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis and updates: ##ESPR #esperion #MDGL #madrigal #MYOV #myovant #PCRX #pacira #PGEN #precigen #ZIOP #ziopharm #ZYNE #zynerba
MTSL Issue 929
MTSL Issue 929 (dated 06/18/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #BMRN #biomarin #ESPR #esperion #INCY #incyte #MYOV #myovant #SGMO #sangamo
MTSL Issue 928
MTSL Issue 928 (dated 05/28/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #MYOV #myovant #ZYNE #zynerba
MTSL Issue 926
MTSL Issue 926 (dated 04/30/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #ESPR #esperion #INCY #incyte #IONS #ionis #MYOV #myovant #PGEN #precigen #SGMO #sangamo
MTSL Issue 924
MTSL Issue 924 (dated 04/02/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #INCY #incyte #MYOV #myovant
MTSL Issue 921
MTSL Issue 921 (dated 02/20/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #FPX #fiveprime #INCY #incyte #MYOV #myovant #PCRX #pacira #PGEN #precigen
Myovant (MYOV) — Relugolix Uterine Fibroids Data Highly Competitive
BIOINVEST BREAKING NEWS – A very positive long-term follow-up (88% response rate) from the LIBERTY trial was released yesterday and we believe continues to further solidify relugolix in uterine fibroids (UF). Management will file for an NDA for the use of relugolix+ABT in UF in April (plus a separate filing for the treatment of relugoxi in prostate cancer in Q2:20). For relugolix in endometriosis, we expect MYOV to (…more)
MTSL Issue 919
MTSL Issue 919 (dated 01/23/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ESPR #esperion #FPRX #fiveprime #IONS #ionis #INCY #incyte #MDGL #madrigal #MYOV #myovant #NKTR #nektar #PCRX #pacira #ZIOP #ziopharm
Top Picks 2020: Myovant Sciences Ltd. (MYOV)
Myovant Sciences Ltd. (MYOV) offers a new drug “pipeline in a pill”, asserts biotech expert Jay Silverman, contributing editor to Medical Technology Stock Letter.
MTSL Issue 918
MTSL Issue 918 (dated 01/09/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #biomarin #XON #intrexon #INCY #incyte #MYOV #myovant #NKTR #nektar #PCRX #pacira #SGMO #sangamo
MTSL Issue 916
MTSL Issue 916 (dated 12/06/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #MDCO #medicinescompany #MYOV #myovant #SGMO #sangamo #ZIOP #ziopharm
Myovant (MYOV) — Time Loves a HERO as MYOV Delivers Excellent Phase III Data for Advanced Prostate Cancer
BIOINVEST BREAKING NEWS – Myovant (MYOV) Legendary blues rockers Little Feat song, âTime Loves a Hero,â says it all for MYOV today as their Phase III prostate cancer data from HERO trial was excellent. Patient MYOV investors were rewarded this morning as the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. (…more)
MTSL Issue 915
MTSL Issue 915 (dated 11/15/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ALKS #alkermes #ESPR #esperion #FPRX #fiveprime #MDGL #madrigal #MYOV #myovant #PCRX #pacira ##SGMO #sangamo #ZIOP #ziopharm #ZYNE #zynerba
MTSL Issue 914
MTSL Issue 914 (dated 11/01/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ALKS #alkermes #INCY #incyte #MDGL #madrigal #MDCO #medicinescompany #MYOV #myovant
MTSL Issue 909
MTSL Issue 909 (dated 8/22/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #incyte #XON #intrexon #MYOV #myovant
MTSL Issue 907
MTSL Issue 907 (dated 7/25/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #IONS #ionis #MYOV #myovant #NKTR #nektar
MTSL Issue 902
MTSL Issue 902 (dated 5/16/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR FPRX #INCY #MYOV #NKTR #SGMO #ZIOP
MTSL Issue 896
MTSL Issue 896 (dated 2/14/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #INCY #incyte #MYOV #myovant #NKTR #nektar #PCRX #pacira #SGMO #sangamo #ZIOP #ziopharm
MTSL Issue 894
MTSL Issue 894 (dated 1/17/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MYOV #NKTR #PCRX #SGMO
MTSL Issue 888
MTSL Issue 888 (dated 10/18/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #FPRX #IONS #MYOV #ZIOP
MTSL Issue 882
MTSL Issue 882 (dated 07/19/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #MDGL #MYOV #PCRX #SGMO #CRSP #EDIT #NTLA
Myovant: Drug Offers ‘Best-in-Class’ Potential
Myovant Sciences Ltd. (MYOV:NYSE) is an emerging biotech leader focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.
MTSL Issue 864
MTSL Issue 864 (dated 11/09/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ESPR #FPRX #INCY #IONS #MDCO #MYOV #NKTR #PCRX #SGMO #ZIOP